Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer

Brazilian cohort results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer

PRECONNECT is a multicenter study demonstrating the efficacy and tolerability of trifluridine/tipiracil in adult patients with histologically confirmed adenocarcinoma of the colon or rectum and pretreated metastatic lesions. The current article describes the characteristics and outcomes of the Brazi...

Full description

Bibliographic Details
Main Authors:	Celso Abdon Lopes de Mello, Felipe Melo Cruz, Fernando Meton de Alencar Camara Vieira, Alan Arrieira Azambuja, Luiz A Senna Leite, Luciana Mardegan, Andreia Gil, Loïck Vidot, Anelisa Coutinho
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia 2022-12-01
Series:	Brazilian Journal of Oncology
Subjects:	trifluridine/tipiracil colorectal cancer metastatic colorectal cancer refractory disease
Online Access:	https://www.brazilianjournalofoncology.com.br/details/225/en-US/brazilian-cohort-results-of-the-preconnect-study--safety-and-efficacy-of-trifluridine-tipiracil-in-metastatic-colorectal-cancer

Similar Items

Efficacy and tolerability of trifluridine/tipiracil in patients with refractory metastatic colorectal cancer at the general hospital of Šibenik-Knin country
by: Lana Jajac-Bručić, et al.
Published: (2021-01-01)

Long-Term Survival in a Patient with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil as Late-Line Chemotherapy: A Case Report
by: Bülent Karabulut, et al.
Published: (2024-06-01)

Trifluridine–tipiracil plus bevacizumab versus trifluridine–tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2024-06-01)

Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
by: Toshiaki Takahashi, et al.
Published: (2025-01-01)

The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis
by: M.João de Sousa, et al.
Published: (2022-01-01)

Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01)

Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
by: G. Sommerhäuser, et al.
Published: (2022-07-01)

PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer
by: T. Sakakida, et al.
Published: (2024-09-01)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
by: Meng-Che Hsieh, et al.
Published: (2022-05-01)

Eco-friendly HPTLC method for Trifluridine and Tipiracil determination: Quality-by-design meets green analytical chemistry
by: Amruta Balekundri, et al.
Published: (2025-06-01)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
by: Celia Lara-Morga, et al.
Published: (2023-04-01)

Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
by: Wang X, et al.
Published: (2020-04-01)

TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context
by: Lene Baeksgaard Jensen, et al.
Published: (2024-04-01)

Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis
by: Daniel Sur, et al.
Published: (2022-10-01)

Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer
by: Stefan Kasper, et al.
Published: (2018-11-01)

Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting
by: Mohamed ELBassiouny
Published: (2023-03-01)

Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
by: Daniel Tong, et al.
Published: (2021-06-01)

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
by: Carlo Signorelli, et al.
Published: (2023-06-01)

Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
by: Long-Zhuan Huang, et al.
Published: (2024-11-01)

Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study
by: Yukiya Narita, et al.
Published: (2024-06-01)

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context
by: Niels A.D. Guchelaar, et al.
Published: (2025-02-01)

Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
by: Keigo Chida, et al.
Published: (2021-03-01)

Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme
by: Timothy Iveson, et al.
Published: (2020-02-01)

Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer
by: K. Fukuda, et al.
Published: (2024-03-01)

Applicable Pharmacokinetic Study: Development and Validation of Bioanalytical LC-MS/MS Method for Simultaneous Determination of Tipiracil, Trifluridine and Its Two Metabolites 5-Trifluoromethyluracil, 5-Carboxy 2′-Deoxyuridine in Rat Plasma
by: Manal El-Gendy, et al.
Published: (2023-12-01)

Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study
by: Carlo Signorelli, et al.
Published: (2024-12-01)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
by: Daisuke Kotani, et al.
Published: (2019-12-01)

Beneficial Treatment Management with Trifluridine/Tipiracil in a Patient with Metastatic Colorectal Cancer and Pronounced Hematological Event History during Previous Treatments
by: Volker Kaechele, et al.
Published: (2018-01-01)

Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab
by: Kazuki Nozawa, et al.
Published: (2020-11-01)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
by: Naoki Takahashi, et al.
Published: (2023-08-01)

TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
by: Ritam Joarder, et al.

Innovations in colorectal cancer treatment: trifluridine and tipiracil with bevacizumab for improved outcomes – a review
by: Taruba Rais, et al.
Published: (2024-07-01)

Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
by: Ruohong Lin, et al.
Published: (2024-12-01)

Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice
by: M. Yu. Fedyanin
Published: (2020-12-01)

Impact of renal impairment on early development of severe neutropenia with trifluridine/tipiracil treatment for metastatic colorectal cancer
by: Yoshitaka Saito, et al.
Published: (2024-11-01)

Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database
by: Yongli Hu, et al.
Published: (2024-07-01)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases
by: Nicholas Fidelman, et al.
Published: (2022-12-01)

TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study
by: Giuseppe Cicero, et al.
Published: (2020-09-01)